Phenotypeca wins a voucher to explore how the genetic diversity of Saccharomyces cerevisiae can be exploited for the production of VLPs with The Future Vaccine Manufacturing Research Hub (Vax-Hub)
This Vax-Hub Interaction Voucher will facilitate a new collaboration between scientists from the Jenner Institute and Phenotypeca Ltd to assess if the genetic diversity of strains of Saccharomyces cerevisiae can be used to enhance the production of virus-like particle (VLP) vaccines.
Yeast has been safely used for many years to produce VLP vaccines, e.g. for Hepatitis B (an enveloped capsid) and Human Papillomavirus (a non enveloped capsid) vaccines. However, little optimisation work has been done and the yeast characteristics needed for efficient VLP production are still unknown.
Of all the yeast species, Saccharomyces cerevisiae is the most studied (being the model eukaryote), with well-developed tools that allow its manipulation and optimisation. This know-how, combined with Phenotypeca’s novel yeast libraries containing up to a billion genetically distinct individuals, will be evaluated for improving VLP vaccines to make them more available to those who need them.
For more information about the work of Vax-Hub see https://www.ucl.ac.uk/biochemical-engineering/research/research-and-training-centres/vax-hub